The drug will be available in the Indian market under the brand name FabiFlu at Rs 103 per tablet
R0 values, or the average number of infections expected to be caused by a Covid carrier, vary between states, and have not stabilised. While unlocking, it would be wise to look at these variations
We are not talking about an immunity booster. We are talking about a cure," said Acharya Balkrishna, managing director of Patanjali
The approval process for remdesivir was accelerated in view of the emergency situation
Gupta and Sharma talk to Geetanjali Krishna about why India is always in the midst of some disaster or the other and how people could build resilience
Plan for substantially changing revenue mix over 3 years
Company to expand across India in next two years and also enter into new therapy areas through a combination of organic and inorganic routes